Improved Survival in Patients With NSCLC and Brain Metastases Improved Survival in Patients With NSCLC and Brain Metastases

About a third of the patients with NSCLC and brain metastases treated with atezolizumab in combination with chemotherapy had overall survival improved to 2 years.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news